



**edap tms**  
Bringing New Horizons to Therapy

## **EDAP to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event**

January 5, 2021

LYON, France, January 5, 2021 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy based therapies, today announced that it will participate in the 10<sup>th</sup> Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Marc Oczachowski, President and CEO, will host 1x1 meetings and will present a corporate update on Thursday, January 7<sup>th</sup> at 9am EST/ 2pm GMT /3pm CET.

To register to listen to the presentation or to request a meeting, visit: <http://lifesci.events/LifeSci2021>. To access the subsequent archived recording of this presentation, please visit the Investor Relations section of the EDAP website or [click here](#).

### **About EDAP TMS SA**

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, and [us.hifu-prostate.com](http://us.hifu-prostate.com).

### **Forward-Looking Statements**

In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

### **Company Contact**

Blandine Confort  
Investor Relations / Legal Affairs  
EDAP TMS SA  
+33 4 72 15 31 50  
[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

### **Investor Contact**

Jeremy Feffer  
LifeSci Advisors, LLC  
212-915-2568  
[jeremy@lifesciadvisors.com](mailto:jeremy@lifesciadvisors.com)



**edap tms**  
Bringing New Horizons to Therapy

Source: EDAP TMS S.A.